CLOs on the Move

ProNAi

www.pronai.com

 
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.pronai.com
  • 2150 – 885 West Georgia Street
    Vancouver, BC CAN V6C 3E8
  • Phone: 604.558.6536

Executives

Name Title Contact Details

Similar Companies

Perlan Therapeutics Inc

Perlan Therapeutics Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

DynPort Vaccine Company

DynPort Vaccine Company LLC (DVC) provides an integrated approach for the advanced development of specific vaccines and other products to protect our nation against the threat of bio-warfare agents. This development effort includes process refinement,

Enalare Therapeutics

Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.

Harkness Pharmaceuticals

Harkness Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Amerigen Pharmaceuticals Inc

Amerigen Pharmaceuticals Inc is a East Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.